Healios K.K. (HLOSF)
USD 1.35
(0.0%)
USD 1.35
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.53 Billion JPY | 8218.48% |
| 2022 | 54.48 Million JPY | -47.54% |
| 2021 | 103.84 Million JPY | -5.97% |
| 2020 | 110.44 Million JPY | 17.23% |
| 2019 | 94.21 Million JPY | -96.51% |
| 2018 | 2.69 Billion JPY | 13.83% |
| 2017 | 2.37 Billion JPY | -5.16% |
| 2016 | 2.5 Billion JPY | 0.0% |
| 2015 | - JPY | 0.0% |
| 2014 | - JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 6.09 Billion JPY | 35.05% |
| 2024 Q1 | 29.83 Million JPY | -0.35% |
| 2023 Q1 | 53.65 Million USD | -1.52% |
| 2023 FY | 4.53 Billion JPY | 8218.48% |
| 2023 Q3 | 47.49 Million USD | -3.61% |
| 2023 Q4 | 32.11 Million USD | -32.37% |
| 2023 Q2 | 49.27 Million USD | -8.16% |
| 2022 Q3 | 49.47 Million JPY | -45.63% |
| 2022 FY | 54.48 Million JPY | -47.54% |
| 2022 Q4 | 54.48 Million JPY | 10.12% |
| 2022 Q1 | 12.29 Billion JPY | 2.85% |
| 2022 Q2 | 91 Million JPY | -99.26% |
| 2021 Q1 | 104 Million JPY | -99.09% |
| 2021 FY | 103.84 Million JPY | -5.97% |
| 2021 Q4 | 11.95 Billion JPY | 2.33% |
| 2021 Q3 | 11.68 Billion JPY | 11092.88% |
| 2021 Q2 | 104.38 Million JPY | 0.36% |
| 2020 FY | 110.44 Million JPY | 17.23% |
| 2020 Q1 | 10.66 Billion JPY | 4.17% |
| 2020 Q2 | 10.74 Billion JPY | 0.7% |
| 2020 Q3 | 10.81 Billion JPY | 0.73% |
| 2020 Q4 | 11.4 Billion JPY | 5.4% |
| 2019 Q1 | 2.65 Billion JPY | -8.63% |
| 2019 Q4 | 10.23 Billion JPY | -11.5% |
| 2019 Q3 | 11.57 Billion JPY | 342.79% |
| 2019 Q2 | 2.61 Billion JPY | -1.62% |
| 2019 FY | 94.21 Million JPY | -96.51% |
| 2018 FY | 2.69 Billion JPY | 13.83% |
| 2018 Q4 | 2.9 Billion JPY | 6.02% |
| 2018 Q2 | 2.78 Billion JPY | 19.63% |
| 2018 Q3 | 2.74 Billion JPY | -1.54% |
| 2018 Q1 | 2.32 Billion JPY | -1.81% |
| 2017 Q3 | 2.41 Billion JPY | -1.75% |
| 2017 FY | 2.37 Billion JPY | -5.16% |
| 2017 Q1 | 2.5 Billion JPY | 0.0% |
| 2017 Q2 | 2.45 Billion JPY | -1.72% |
| 2017 Q4 | 2.37 Billion JPY | -1.78% |
| 2016 FY | 2.5 Billion JPY | 0.0% |
| 2016 Q4 | 2.5 Billion JPY | 0.0% |
| 2016 Q3 | 2.5 Billion JPY | 0.0% |
| 2016 Q2 | 2.5 Billion JPY | 0.0% |
| 2016 Q1 | 2.5 Billion JPY | 0.0% |
| 2015 FY | - JPY | 0.0% |
| 2015 Q3 | - JPY | 0.0% |
| 2015 Q2 | - JPY | 0.0% |
| 2015 Q4 | - JPY | 0.0% |
| 2014 FY | - JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -10899.199% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -109847.775% |
| SQZ Biotechnologies Company | 27.47 Million USD | -16397.397% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -10348.897% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -15124.842% |
| Mesoblast Limited | 118.7 Million USD | -3718.015% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -477822.45% |
| Genus plc | 233.1 Million USD | -1844.23% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -154555.288% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -337206.785% |
| Marizyme, Inc. | 18.71 Million USD | -24112.643% |
| ContraFect Corporation | 2.88 Million USD | -157206.491% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -604166.667% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -3344870.366% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -313247.194% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -194744.698% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -79993.978% |
| MultiCell Technologies, Inc. | 202.58 USD | -2237140782.614% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -7783.247% |
| EV Biologics, Inc. | 1.49 Million USD | -303094.311% |
| Q BioMed Inc. | 4.1 Million USD | -110168.15% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -13591.429% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -719177.168% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -368846.914% |
| Biomind Labs Inc. | 735.54 Thousand USD | -616044.285% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | -2541.872% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -34769.599% |
| Skye Bioscience, Inc. | 4.61 Million USD | -98095.857% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -510223.58% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -3202319.48% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -77091.799% |
| IMV Inc. | 28.88 Million USD | -15590.403% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -17621113.889% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -200574.731% |
| GB Sciences, Inc. | 1.75 Million USD | -257501.431% |
| Alpha Cognition Inc. | 1.22 Million USD | -371262.175% |
| HST Global, Inc. | 98.31 Thousand USD | -4609385.45% |
| CSL Limited | 12.18 Billion USD | 62.801% |
| Halberd Corporation | 150 Thousand USD | -3021233.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -454765.718% |
| Resverlogix Corp. | 6.49 Million USD | -69719.75% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -949009.948% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1773038.439% |
| argenx SE | 20 Million USD | -22560.0% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -9847.322% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -167212.548% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -44322638.386% |
| Genscript Biotech Corporation | 417.73 Million USD | -984.889% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -2258942.15% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -188912.58% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1976427.644% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -6599.895% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -149659.219% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1259803.811% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -22194.372% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -3048590.247% |
| BioStem Technologies, Inc. | 4.71 Million USD | -96091.868% |
| ONE Bio Corp. | 19.71 Million USD | -22887.548% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1811381.242% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1822029.302% |
| Agentix Corp. | 50 Thousand USD | -9063900.0% |
| LadRx Corporation | 33.6 Thousand USD | -13485587.08% |
| Cell Source, Inc. | 9.25 Million USD | -48872.496% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -599209.181% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -599209.181% |
| NovAccess Global Inc. | 2.19 Million USD | -205911.237% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -63976.371% |
| Itoco Inc. | 228.37 Thousand USD | -1984338.013% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -2148021.815% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -90849.227% |
| Kadimastem Ltd | 891.22 Thousand USD | -508412.992% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1127686.805% |
| CytoDyn Inc. | 30.07 Million USD | -14968.493% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -935714.522% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1287959.867% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -57854.261% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3699491.837% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1461835.484% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -95607.077% |
| International Stem Cell Corporation | 4.17 Million USD | -108372.954% |
| Bioxytran, Inc. | 1.92 Million USD | -235328.571% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -7261207.74% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -207704.118% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -54397.354% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -52689.75% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -291257.196% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1690944.776% |
| Neutra Corp. | 54.15 Thousand USD | -8368317.165% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -247550.273% |
| PureTech Health plc | 25.51 Million USD | -17664.189% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -370093.085% |
| IXICO plc | 472.02 Thousand USD | -960022.706% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -29136.823% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -7178.801% |
| CSL Limited | 12.18 Billion USD | 62.801% |
| Cellectis S.A. | 92.77 Million USD | -4784.857% |